As the debate over a draft resolution supporting greater price transparency for medicines in national and global markets intensifies, with closed-door consultations among countries at the 72nd World Health Assembly continuing late into the night, Health Policy Watch continues to feature diverse “Inside Views” on this charged issue. Here, Suerie Moon, MPA PhD, faculty member at the Graduate Institute of Geneva and Harvard T.H. Chan School of Public Health and researcher into medicines access policies, examines the evidence behind the debate over whether greater transparency can really help reduce prices.Continue reading ->

The fate of a potentially game-changing World Health Assembly resolution that would support greater national and global transparency in drug pricing remained in the balance today as the country co-sponsors tabled a resolution riddled with comments and caveats, and a “drafting group” was urgently formed to huddle on ways to move forward on a compromise text.Continue reading ->

Image Credits: Pxhere.

[Re-posted from Knowledge Ecology International.]

Perhaps the toughest issue in the 72nd World Health Assembly negotiations on a WHO transparency resolution concerns the proposal to require public reporting of the costs of each clinical trial undertaken for development of drugs, vaccines, cell- and gene-therapies and diagnostic tests.Continue reading ->

Image Credits: Dashiell Love.